International Journal of Clinical Research

Among diabetic fundus complications, diabetic retinopathy (DR) has the highest incidence. At present, the main treatment methods for proliferative diabetic retinopathy (PDR) include drug therapy, laser photocoagulation therapy, glucocorticoid therapy, anti-vascular endothelial growth factor (VEGF) therapy and surgical therapy. Panretinal photocoagulation is considered as the preferred method for vision restoration in DR Patients, but it may cause a series of side effects due to laser damage. Compared to laser therapy, drug therapy can provide intervention at all stages of DR Disease, and can also effectively maintain the anatomical shape of the retina, thus reducing the side effects caused by laser. VEGF drugs work by blocking the activity of VEGF, thereby preventing the formation of new blood vessels in the eye, and at the same time, can reduce the transparency of blood vessels and reduce blood leakage, which is the focus of current research on the delayed development of PDR. In this paper, the use of VEGF in proliferative diabetic retinopathy will be summarized, and through the review of recent studies and literature reports, new ideas for the treatment of diabetic retinopathy will be provided.

Diabetes; Proliferative diabetes retinopathy; Anti vascular endothelial growth factor; Research progress